Related Experiment Video
Updated: Jul 12, 2026

Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
Long-Term Hemodynamic Stabilization With TTR-Stabilizing Therapy and Pressure-Guided Management in ATTR
Jamschid Sedighi1, Bernhard Unsöld1, Priyanka Boettger1
1Department of Cardiology and Angiology, Justus Liebig University Giessen, Giessen, Germany.
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) treatment with stabilizing therapy and pulmonary artery pressure (PAP) monitoring improved heart function. This case suggests PAP-guided management may aid ATTR-CM patients on disease-modifying drugs.
Area of Science:
- Cardiology
- Pharmacology
- Medical Devices
Background:
- Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is often underdiagnosed in heart failure with preserved ejection fraction (HFpEF).
- Disease-modifying therapies for ATTR-CM can slow progression, but their long-term impact on hemodynamics is not fully understood.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Cardiomyopathy II: Dilated Cardiomyopathy
Aortic Regurgitation III: Medical Management
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure VI: Adjunct Therapies
